Ardelyx Inc
NASDAQ:ARDX

Watchlist Manager
Ardelyx Inc Logo
Ardelyx Inc
NASDAQ:ARDX
Watchlist
Price: 6.09 USD -0.98% Market Closed
Market Cap: 1.5B USD

Ardelyx Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ardelyx Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Ardelyx Inc
NASDAQ:ARDX
Revenue
$398.2m
CAGR 3-Years
253%
CAGR 5-Years
118%
CAGR 10-Years
29%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Ardelyx Inc
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Ardelyx Inc. is a biopharmaceutical company that operates at the nexus of innovative drug development, focusing primarily on pioneering treatments for cardiorenal and gastrointestinal diseases. Founded in 2007, Ardelyx has carved a niche for itself by targeting novel therapeutics to address unmet medical needs. The company's flagship product, tenapanor, exemplifies its core strategy. Tenapanor is designed to treat hyperphosphatemia in patients with chronic kidney disease on dialysis by inhibiting the NHE3 sodium transporter in the gut. This mechanism not only addresses phosphate levels but also showcases Ardelyx's approach of modifying pathways at their source to provide significant clinical benefits. The company navigates a complex landscape fraught with regulatory challenges, but its focused pipeline and ability to secure FDA approval for its products underscore its commitment to improving patient outcomes. Ardelyx generates revenue through the commercialization of its products, partnerships, and licensing agreements. The company primarily monetizes tenapanor, its leading therapeutic, which has gained traction in both U.S. and international markets. While the initial stages of bringing a drug to market involve substantial investment in research and development, regulatory approvals, and marketing, Ardelyx's strategic collaborations further augment its revenue streams. These partnerships, often with larger pharmaceutical entities, provide avenues for both upfront payments and milestone achievements as conditions are met. This multifaceted approach not only sustains the company financially but also enhances its capacity to innovate and expand its therapeutic horizons in the biopharmaceutical industry.

ARDX Intrinsic Value
12.02 USD
Undervaluation 49%
Intrinsic Value
Price

See Also

What is Ardelyx Inc's Revenue?
Revenue
398.2m USD

Based on the financial report for Sep 30, 2025, Ardelyx Inc's Revenue amounts to 398.2m USD.

What is Ardelyx Inc's Revenue growth rate?
Revenue CAGR 10Y
29%

Over the last year, the Revenue growth was 58%. The average annual Revenue growth rates for Ardelyx Inc have been 253% over the past three years , 118% over the past five years , and 29% over the past ten years .

Back to Top